Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
594 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00261846 | Study Evaluating SKI-606 (Bosutinib) In Philadelphia Chromosome Positive Leukemias | completed | Phase 2 | 571 | PfizerINDUSTRY | 27 | Jul 27, 2017 | clinicaltrials |
| NCT01911728 | Drug-drug Interaction Study With MDV3100 and a Cocktail of Substrates | completed | Phase 1 | 14 | Astellas Pharma Europe B.V.INDUSTRY | 1 | Jun 26, 2017 | clinicaltrials |
| NCT00074152 |
| Adjuvant Chemotherapy in Treating Women Who Have Undergone Resection for Relapsed Breast Cancer; Chemotherapy as Adjuvant for LOcally Recurrent Breast Cancer(CALOR) |
| completed |
| Phase 3 |
| 162 |
| ETOP IBCSG Partners FoundationNETWORK |
| 10 |
| Jun 16, 2017 |
| clinicaltrials |
| NCT01172548 | Safety and Efficacy Evaluation of Two Year Imatinib Treatment in Adjuvant Gastrointestinal Stromal Tumor (GIST)(INV555) | completed | Phase 2 | 132 | Novartis PharmaceuticalsINDUSTRY | 12 | May 31, 2017 | clinicaltrials |
| NCT00925600 | Evaluation of New or Worsening Lens Opacifications in Men With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss | completed | Phase 3 | 769 | AmgenINDUSTRY | 18 | May 30, 2017 | clinicaltrials |
| NCT01360554 | ARCHER 1009 : A Study Of Dacomitinib (PF-00299804) Vs. Erlotinib In The Treatment Of Advanced Non-Small Cell Lung Cancer(ARCHER 1009) | completed | Phase 3 | 878 | PfizerINDUSTRY | 23 | May 24, 2017 | clinicaltrials |
| NCT00294658 | Thymectomy Trial in Non-Thymomatous Myasthenia Gravis Patients Receiving Prednisone Therapy | completed | Phase 3 | 126 | University of Alabama at BirminghamOTHER | 18 | May 23, 2017 | clinicaltrials |
| NCT00041119 | Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer | completed | Phase 3 | 3,871 | Alliance for Clinical Trials in OncologyOTHER | 2 | May 18, 2017 | clinicaltrials |
| NCT01193244 | Study Comparing Orteronel Plus Prednisone in Participants With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer | completed | Phase 3 | 1,560 | Millennium Pharmaceuticals, Inc.INDUSTRY | 40 | May 17, 2017 | clinicaltrials |
| NCT00045032 | Herceptin (Trastuzumab) in Treating Women With Human Epidermal Growth Factor Receptor (HER) 2-Positive Primary Breast Cancer(HERA) | completed | Phase 3 | 5,099 | Hoffmann-La RocheINDUSTRY | 33 | Apr 27, 2017 | clinicaltrials |
| NCT01308580 | Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer(PROSELICA) | completed | Phase 3 | 1,200 | SanofiINDUSTRY | 22 | Apr 17, 2017 | clinicaltrials |
| NCT00384176 | First Line Metastatic Colorectal Cancer Therapy in Combination With FOLFOX(HORIZON III) | completed | Phase 2 / Phase 3 | 1,814 | AstraZenecaINDUSTRY | 28 | Apr 14, 2017 | clinicaltrials |
| NCT00719264 | Safety and Efficacy of Bevacizumab Plus RAD001 Versus Interferon Alfa-2a and Bevacizumab for the First-line Treatment in Adult Patients With Kidney Cancer | completed | Phase 2 | 365 | Novartis PharmaceuticalsINDUSTRY | 21 | Mar 20, 2017 | clinicaltrials |
| NCT01572727 | A Study of the Experimental Drug BKM120 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast Cancer, With or Without PI3K Activation(BELLE-4) | completed | Phase 2 / Phase 3 | 416 | Novartis PharmaceuticalsINDUSTRY | 22 | Mar 9, 2017 | clinicaltrials |
| NCT00976989 | A Study of Pertuzumab in Combination With Herceptin and Chemotherapy in Participants With HER2-Positive Breast Cancer | completed | Phase 2 | 225 | Hoffmann-La RocheINDUSTRY | 20 | Feb 6, 2017 | clinicaltrials |
| NCT00080262 | Novel Epothilone (BMS-247550) in Patients With Metastatic Breast Cancer (MBC) | completed | Phase 2 | 125 | R-PharmINDUSTRY | 10 | Jan 30, 2017 | clinicaltrials |
| NCT00154102 | Cetuximab Combined With Irinotecan in First-line Therapy for Metastatic Colorectal Cancer (CRYSTAL)(CRYSTAL) | completed | Phase 3 | 1,221 | Merck KGaA, Darmstadt, GermanyINDUSTRY | 30 | Jan 30, 2017 | clinicaltrials |
| NCT01870609 | Placebo Controlled Study of VS-6063 in Subjects With Malignant Pleural Mesothelioma(COMMAND) | terminated | Phase 2 | 344 | Verastem, Inc.INDUSTRY | 15 | Jan 30, 2017 | clinicaltrials |
| NCT02829775 | A Study of Continued Treatment Among Participants Who Have Responded to Peginterferon Alfa-2a (Pegasys®) or Recombinant Interferon Alfa-2a (Roferon-A®) in Prior Clinical Studies | completed | Phase 2 / Phase 3 | 9 | Hoffmann-La RocheINDUSTRY | 7 | Jan 9, 2017 | clinicaltrials |
| NCT00003596 | Chemotherapy Plus Radiation Therapy in Treating Patients With Stage II or Stage III Anal Cancer | completed | Phase 3 | 682 | Radiation Therapy Oncology GroupNETWORK | 2 | Jan 4, 2017 | clinicaltrials |
| NCT01765543 | A Pharmacokinetics (PK) Study to Investigate the Effect of Rifampin on PK of Vemurafenib (Zelboraf) | completed | Phase 1 | 27 | Hoffmann-La RocheINDUSTRY | 5 | Dec 15, 2016 | clinicaltrials |
| NCT01369329 | A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1) | completed | Phase 3 | 769 | Janssen Research & Development, LLCINDUSTRY | 23 | Dec 7, 2016 | clinicaltrials |
| NCT01450696 | A Study of Herceptin (Trastuzumab) in Combination With Cisplatin/Capecitabine Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Gastric or Gastro-Esophageal Junction Cancer(HELOISE) | terminated | Phase 3 | 296 | Hoffmann-La RocheINDUSTRY | 25 | Nov 28, 2016 | clinicaltrials |
| NCT00021255 | Combination Chemotherapy With or Without Trastuzumab in Treating Women With Breast Cancer | completed | Phase 3 | 3,222 | SanofiINDUSTRY | 42 | Nov 15, 2016 | clinicaltrials |
| NCT01674907 | An Observational Study of Avastin (Bevacizumab) in First Line in Patients With Metastatic Colorectal Cancer (AVANiS) | completed | — | 27 | Hoffmann-La RocheINDUSTRY | 1 | Nov 2, 2016 | clinicaltrials |
| NCT00744497 | Randomized Study Comparing Docetaxel Plus Dasatinib to Docetaxel Plus Placebo in Castration-resistant Prostate Cancer(READY) | completed | Phase 3 | 1,930 | Bristol-Myers SquibbINDUSTRY | 25 | Oct 17, 2016 | clinicaltrials |
| NCT00858871 | First Line Hepato Cellular Carcinoma (HCC)(BRISK FL) | completed | Phase 3 | 1,714 | Bristol-Myers SquibbINDUSTRY | 26 | Oct 17, 2016 | clinicaltrials |
| NCT00498797 | E3-Hormone Refractory Prostrate Cancer Taxotere Combination | completed | Phase 2 | 86 | SanofiINDUSTRY | 5 | Oct 7, 2016 | clinicaltrials |
| NCT00069095 | A Study of Capecitabine (Xeloda) and Bevacizumab as a First-line Therapy in Patients With Metastatic Colorectal Cancer | completed | Phase 3 | 2,035 | Hoffmann-La RocheINDUSTRY | 33 | Oct 6, 2016 | clinicaltrials |
| NCT00494481 | E3 Breast Cancer Taxotere Combination | completed | Phase 2 | 64 | Genzyme, a Sanofi CompanyINDUSTRY | 5 | Sep 30, 2016 | clinicaltrials |
| NCT00056407 | "REDUCE" - A Clinical Research Study To Reduce The Incidence Of Prostate Cancer In Men Who Are At Increased Risk(REDUCE) | completed | Phase 3 | 8,231 | GlaxoSmithKlineINDUSTRY | 42 | Sep 23, 2016 | clinicaltrials |
| NCT00022516 | Low-dose Oral Cyclophosphamide and Methotrexate Maintenance for Hormone Receptor-negative Early Breast Cancer(22-00) | completed | Phase 3 | 1,086 | ETOP IBCSG Partners FoundationNETWORK | 11 | Sep 16, 2016 | clinicaltrials |
| NCT00071188 | ZD6474 Alone or in Combination With Paclitaxel and Carboplatin in Subjects With Previously Untreated Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) | completed | Phase 2 | — | Genzyme, a Sanofi CompanyINDUSTRY | 9 | Aug 25, 2016 | clinicaltrials |
| NCT00123474 | Chronic Myelogenous Leukemia (CML) - Follow on: Study of BMS-354825 in Subjects With CML | completed | Phase 3 | 724 | Bristol-Myers SquibbINDUSTRY | 31 | Aug 25, 2016 | clinicaltrials |
| NCT00059722 | This Study is to Compare the Efficacy of ZD6474 and ZD1839 in Subjects With NSCLC. | completed | Phase 2 | 160 | Genzyme, a Sanofi CompanyINDUSTRY | 6 | Aug 24, 2016 | clinicaltrials |
| NCT00162123 | A Companion Study for Patients Enrolled in Prior/Parent Ipilimumab Studies | completed | Phase 2 | 248 | Bristol-Myers SquibbINDUSTRY | 18 | Jul 27, 2016 | clinicaltrials |
| NCT00519285 | Aflibercept in Combination With Docetaxel in Metastatic Androgen Independent Prostate Cancer(VENICE) | completed | Phase 3 | 1,224 | SanofiINDUSTRY | 31 | Jul 22, 2016 | clinicaltrials |
| NCT00769704 | Efficacy and Safety Study of Talimogene Laherparepvec Compared to Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) in Melanoma | completed | Phase 3 | 437 | BioVex LimitedINDUSTRY | 4 | Jul 13, 2016 | clinicaltrials |
| NCT01528345 | Trial Evaluating Dovitinib Combined With Fulvestrant, in Postmenopausal Patients With HER2- and HR+ Breast Cancer | terminated | Phase 2 | 97 | Novartis PharmaceuticalsINDUSTRY | 15 | Jul 11, 2016 | clinicaltrials |
| NCT01241396 | A Study to Record in an Observational Manner the Treatment of Multiple Myeloma as it is Being Done in Every Day Practice Without Providing Any Investigational Drug or Prescribing Any Procedure | completed | — | 2,396 | Janssen Pharmaceutica N.V., BelgiumINDUSTRY | 21 | Jun 20, 2016 | clinicaltrials |
| NCT01494506 | Study of MM-398 With or Without 5-FU/LV, Versus 5-FU/LV in Patients With Metastatic Pancreatic Cancer(NAPOLI-1) | completed | Phase 3 | 417 | Merrimack PharmaceuticalsINDUSTRY | 15 | Jun 17, 2016 | clinicaltrials |
| NCT00785785 | A Study of Nilotinib Versus Imatinib in GIST Patients(ENESTg1) | completed | Phase 3 | 644 | Novartis PharmaceuticalsINDUSTRY | 35 | Jun 16, 2016 | clinicaltrials |
| NCT01239732 | A Study of the Addition of Avastin (Bevacizumab) to Carboplatin and Paclitaxel Therapy in Patients With Ovarian Cancer | completed | Phase 3 | 1,021 | Hoffmann-La RocheINDUSTRY | 37 | Jun 10, 2016 | clinicaltrials |
| NCT00174837 | TRACE: Tirapazamine-Radiation And Cisplatin Evaluation(TRACE) | completed | Phase 3 | 317 | SanofiINDUSTRY | 17 | May 26, 2016 | clinicaltrials |
| NCT00400478 | A Multicentre, Randomized Phase III Study of Rituximab as Maintenance Treatment Versus Observation in Patients With Aggressive B-cell Lymphoma: NHL-13 | completed | Phase 3 | 683 | Arbeitsgemeinschaft medikamentoese TumortherapieOTHER | 26 | May 26, 2016 | clinicaltrials |
| NCT00602745 | S-1 Versus 5-FU Bolus in Metastatic Pancreatic Cancer Patients Previously Treated With Gemcitabine-Based Regimen(S-1 Pancreas) | terminated | Phase 3 | 61 | SanofiINDUSTRY | 17 | May 26, 2016 | clinicaltrials |
| NCT00625664 | Larotaxel + Cisplatin Versus Gemcitabine + Cisplatin in First Line Treatment of Locally Advanced/Metastatic Urothelial Tract or Bladder Cancer(CILAB) | completed | Phase 3 | 337 | SanofiINDUSTRY | 19 | May 5, 2016 | clinicaltrials |
Data updated 23 days agoSource updated unknownsource: clinicaltrials